Clinical Trials
187 trialsNeoADAURA
AstraZeneca
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Eastern Cooperative Oncology Group
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
National Cancer Institute (NCI)
EV-302
Astellas Pharma Inc
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
MYSTIC
AstraZeneca
MK-3475-689
Merck Sharp & Dohme LLC
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
NEPTUNE
AstraZeneca
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Children's Oncology Group
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
CASPIAN
AstraZeneca
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
KEYNOTE-966
Merck Sharp & Dohme LLC
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
SKYSCRAPER-08
Hoffmann-La Roche
POD1UM-304
Incyte Corporation
KEYNOTE-966
Merck Sharp & Dohme LLC
POSEIDON
AstraZeneca
NIAGARA
AstraZeneca
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
AstraZeneca
KEYNOTE-585
Merck Sharp & Dohme LLC
CheckMate901
Bristol-Myers Squibb
KEYNOTE-585
Merck Sharp & Dohme LLC
AcceleRET-Lung
Hoffmann-La Roche
KEYNOTE-859
Merck Sharp & Dohme LLC
CANOPY-1
Novartis
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
KEYNOTE-A18
Merck Sharp & Dohme LLC
CheckMate 648
Bristol-Myers Squibb
LEAP-006
Merck Sharp & Dohme LLC
MK-7684A-007
Merck Sharp & Dohme LLC
KEYNOTE-412
Merck Sharp & Dohme LLC
KEYNOTE-826
Merck Sharp & Dohme LLC
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Children's Oncology Group
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
SWOG Cancer Research Network
CheckMate 816
Bristol-Myers Squibb
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Radiation Therapy Oncology Group
CheckMate 9LA
Bristol-Myers Squibb
MK-3475-811
Merck Sharp & Dohme LLC
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
MK-3475A-D77
Merck Sharp & Dohme LLC
CheckMate 227
Bristol-Myers Squibb
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
LIBRETTO-431
Eli Lilly and Company